Sunbird Bio Secures $14M to Fund Diagnostic Platform

Sunbird Bio, a biotech firm based in Cambridge, has closed a $14 million financing round. The round saw participation from two new investors, Eli Lilly and Company and EDBI (the strategic arm of the Singapore Economic Development Board). 

The company plans to use the funding to advance the clinical development of its diagnostic platform. In support of this, the company will open new laboratory space and initiate additional clinical studies of its diagnostic technology.

Sunbird was founded to address the growing need for improved diagnostic tests. Their technology focuses on improving reliability and sensitivity in diagnostic tests which will, in turn, accelerate drug development.

Sunbird has two core proprietary platforms – APEX and Glympse – which detect and measure proteins and protease activity which indicates the presence and activity of a disease.

Sunbird Bio said that it is actively securing partnerships with biopharma companies and others to advance the development of its platform and conduct clinical studies.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.